Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Updates on DREAMM-6 and DREAMM-2 in R/R myeloma

Rakesh Popat • 12 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Belantamab mafodotin Bortezomib Dexamethasone Selinexor
DREAMM-2 DREAMM-6

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of the University College London Hospitals, London, UK, discusses the safety and tolerability of belantamab mafodotin, a BCMA targeting antibody-drug conjugate, in combination with bortezomib/dexamethasone in relapsed/refractory (R/R) multiple myeloma patients as evaluated in the DREAMM-6 study (NCT03544281) as well against selinexor and dexamethasone as evaluated in the DREAMM-2 study (NCT03525678). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Rakesh Popat

Treatment goals and preferences in RRMM: patients and physicians 2:29
Treatment goals and preferences in RRMM: patients and physicians
Rakesh Popat • 20 Sep 2025
CMV and other viral reactivations in patients with RRMM treated with BCMA-targeted bispecifics 2:32
CMV and other viral reactivations in patients with RRMM treated with BCMA-targeted bispecifics
Rakesh Popat • 20 Sep 2025
The Phase III Quintessential-2 trial of arlo-cel versus SoC in myeloma: trial in progress 1:50
The Phase III Quintessential-2 trial of arlo-cel versus SoC in myeloma: trial in progress
Rakesh Popat • 20 Sep 2025
Initial results of JNJ-79635322, a novel next-generation trispecific antibody, in R/R myeloma 3:36
Initial results of JNJ-79635322, a novel next-generation trispecific antibody, in R/R myeloma
Rakesh Popat • 12 Jun 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals